OpGen to Present Data Showing Acuitas(R) Tests are Effective Tools for Investigating Transmission of "Super Bugs"
September 22 2015 - 8:15AM
OpGen, Inc. (NASDAQ:OPGN) today announced that data on its
Acuitas® Resistome Test and Acuitas Whole Genome Sequence (WGS)
Analysis for multidrug-resistant organisms (MDROs) will be
presented at the American Society for Microbiology's First
Conference on Rapid Next-Generation Sequencing and Bioinformatic
Pipelines for Enhanced Molecular Epidemiologic Investigation of
Pathogens, to be held from September 24 to 27 in Washington, D.C.
Terry Walker, OpGen Senior Vice President of Research and
Development and a presenter at the OpGen-sponsored symposium at the
ASM conference, said, "Our symposium presentation and three posters
underscore our technologies' rapid and highly accurate approach to
determine the genetic variability underlying multidrug resistant
organisms, and how to use that variability to investigate
transmission events, help stop spread, and prevent outbreaks."
Dr. Walker's presentation, entitled "High Resolution Genomic
Analysis of Multidrug-Resistant Organisms using Acuitas Resistome
Test and Whole Genome Sequence Analysis," is scheduled for
September 25 at 12:00 p.m. EDT in the Capitol Room at the Omni
Shoreham Hotel. The lunch symposium will review the two Acuitas
tests and demonstrate OpGen's Whole Genome Sequencing capabilities
for epidemiologic investigations by analyzing thousands of genes
and show the triaging utility of the Acuitas Resistome Test, saving
time and reducing costs associated with high resolution
analysis.
The three posters will be on display September 25 and 26.
Details are as follows:
1. "Acuitas Resistome Test—a
high-throughput triage tool for strain typing by whole genome
sequencing." Genotype resolution of OpGen's Acuitas Resistome test
examines its utility as a hospital triage tool to determine
transmission events and possible treatments.
2. "MLST+ strain typing of
multidrug-resistance organisms (MDROs) using Acuitas Whole Genome
Sequence Analysis." OpGen's Acuitas WGS Analysis was used to create
MLST+ schemas for eight species of drug-resistant bacteria.
3. "Comprehensive analysis of
antibiotic resistance in multidrug-resistant organisms (MDROs) by
whole genome sequencing using Acuitas Whole Genome Sequence
Analysis." OpGen's Acuitas WGS Analysis was used to test a new
database of all beta-lactamase genes to determine antibiotic
resistance in multidrug-resistance organisms.
About MDROs
Multi-drug resistant organisms (MDROs) are common bacteria that
have developed resistance to multiple classes of antibiotics. They
are a leading cause of hospital-acquired infections and are
associated with an increase in morbidity and mortality. Each year,
more than two million Americans acquire infections that are
resistant to antibiotics and of those, 23,000 will die of those
infections. Asymptomatic carriers are at a higher risk of an MDRO
infection and become reservoirs for transmission to other patients
in health care systems if not accurately identified early. Since
there are many types of antibiotic resistant organisms, and the way
they cause disease is dictated by their genetics, knowing the exact
genetic profile of these organisms is a key step to preventing
their ability to infect.
About OpGen
OpGen, Inc. is an early commercial-stage molecular testing and
bioinformatics company focused on assisting healthcare providers to
combat multi-drug resistant organism (MDRO) bacterial infections –
"Superbugs." The Company is addressing this growing public health
threat by rapidly delivering precise, actionable information to
help identify, combat, and prevent the spread of these complex
infections that jeopardize the safety of our hospitals and other
long-term care facilities. OpGen offers a full portfolio of
Acuitas® products including the MDRO Gene Test, the Resistome Test,
microbial Whole Genome Sequence Analysis, Acuitas Lighthouse™ MDRO
Management System and QuickFISH™, a suite of FDA-cleared and
CE-marked diagnostics for rapid molecular testing of positive blood
cultures designed to assure appropriate antibiotic therapy.
Learn more at www.opgen.com
OpGen Forward-Looking Statements
This press release includes statements relating to the company's
products and services. These statements and other statements
regarding our future plans and goals constitute "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934, and
are intended to qualify for the safe harbor from liability
established by the Private Securities Litigation Reform Act of
1995. Such statements are subject to risks and uncertainties that
are often difficult to predict, are beyond our control, and which
may cause results to differ materially from expectations. Factors
that could cause our results to differ materially from those
described include, but are not limited to, the rate of adoption of
our products and services by hospitals, the success of our
commercialization efforts, the effect on our business of existing
and new regulatory requirements, and other economic and competitive
factors. For a discussion of the most significant risks and
uncertainties associated with OpGen's business, please review our
filings with the Securities and Exchange Commission (SEC). You are
cautioned not to place undue reliance on these forward-looking
statements, which are based on our expectations as of the date of
this press release and speak only as of the date of this press
release. We undertake no obligation to publicly update or revise
any forward-looking statement, whether as a result of new
information, future events or otherwise.
CONTACT: OpGen
Michael Farmer
Director, Marketing
(240) 813-1284
mfarmer@opgen.com
InvestorRelations@opgen.com
Investors
LHA
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com
or
Bruce Voss
(310) 691-7100
bvoss@lhai.com
Media
Lisa Guiterman
(301) 217-9353
lisa.guiterman@gmail.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jul 2023 to Jul 2024